Literature DB >> 9536213

Current concepts of polycystic ovary syndrome.

R L Rosenfield1.   

Abstract

Polycystic ovary syndrome (PCOS) may be loosely defined as unexplained hyperandrogenism, with variable degrees of cutaneous symptoms, anovulatory symptoms, and obesity. The vast majority of patients with the full-blown Stein-Leventhal syndrome have functional ovarian hyperandrogenism (FOH). However, FOH often occurs without the LH excess or polycystic ovaries of classic PCOS. Functional adrenal hyperandrogenism (FAH) is often found in the syndrome, but it is less closely associated with anovulatory symptoms than is FOH. The vast majority of FOH seems to arise from abnormal regulation (dysregulation) of ovarian androgen secretion. This typically is due to escape from desensitization to luteinizing hormone (LH); this appears to occur because of a breakdown in the processes that normally coordinate ovarian androgen and oestrogen secretion so as to prevent hyperoestrogenism. Similar dysregulation of adrenal androgen secretion in response to ACTH seems to account for most FAH. Dysregulation of androgen secretion may affect the ovary alone (isolated FOH), the adrenal alone (isolated FAH), or both together. Modest insulin resistance is common in PCOS/FOH, and the resultant hyperinsulinaemia is a major candidate as the cause of the dysregulation. The hyperinsulinaemia may arise from either 'nature' (genetic defects) or 'nurture' (exogenous obesity). Although hyperinsulinaemia alone does not have an obvious effect on steroidogenesis, it may act in genetically predisposed women as a 'second hit' to unmask latent abnormalities in steroidogenesis. The ovary, the adrenal cortex, and several other organs paradoxically function as if responding to the hyperinsulinaemic state in spite of resistance to the effects of insulin on glucose metabolism. PCOS should be viewed as an early manifestation of a hyperinsulinaemic condition that will predispose to cardiovascular and metabolic complications later in life. A subset of PCOS patients appear to have not only insulin resistance but also beta-cell secretory dysfunction, which may indicate a relationship of the disorder to NIDDM. The fundamental genetic defects remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9536213     DOI: 10.1016/s0950-3552(97)80039-9

Source DB:  PubMed          Journal:  Baillieres Clin Obstet Gynaecol        ISSN: 0950-3552


  12 in total

Review 1.  Neuroendocrine consequences of androgen excess in female rodents.

Authors:  Eileen M Foecking; Melissa A McDevitt; Maricedes Acosta-Martínez; Teresa H Horton; Jon E Levine
Journal:  Horm Behav       Date:  2008-01-10       Impact factor: 3.587

Review 2.  Polycystic ovary syndrome in adolescence.

Authors:  Colleen Buggs; Robert L Rosenfield
Journal:  Endocrinol Metab Clin North Am       Date:  2005-09       Impact factor: 4.741

3.  Developmental programming: prenatal testosterone excess disrupts anti-Müllerian hormone expression in preantral and antral follicles.

Authors:  Almudena Veiga-Lopez; Wen Ye; Vasantha Padmanabhan
Journal:  Fertil Steril       Date:  2012-01-14       Impact factor: 7.329

4.  Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep.

Authors:  Hugo H Ortega; Florencia Rey; Melisa M L Velazquez; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2010-02-10       Impact factor: 4.285

Review 5.  Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Semin Reprod Med       Date:  2011-06-27       Impact factor: 1.303

6.  Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep.

Authors:  Almudena Veiga-Lopez; James S Lee; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2010-06-16       Impact factor: 4.736

Review 7.  Animal models of the polycystic ovary syndrome phenotype.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Steroids       Date:  2013-05-20       Impact factor: 2.668

Review 8.  Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset.

Authors:  L Ibáñez; F de Zegher; N Potau
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 9.  The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies.

Authors:  R B Barnes
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 10.  Sheep models of polycystic ovary syndrome phenotype.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Mol Cell Endocrinol       Date:  2012-10-16       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.